- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04070612
National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia. (BIOCEREVANCE)
National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
These autoimmune haematological diseases are rare diseases affecting the child, often very young, and serious and potentially life-threatening. International literature data are scarce, and include individual cases or small series.
They do not allow to determine an optimal therapeutic strategy in case of escape from the first-line treatments. Existing treatments (long-term corticosteroid therapy, immunoglobulins, splenectomy, immunosuppressants, chemotherapies, and more recently anti-CD20 antibodies) are inconsistently effective, and often associated with serious side effects.
The seriousness of these diseases, the therapeutic difficulties, and the absence of a targeted research project in France, led to the implementation of this study.
This study aims to study prospectively the clinical and paraclinical evolution and prognostic factors of autoimmune haemolytic anemias, Evans syndromes and chronic immunological thrombocytopenic purpura of children in France.
Studietype
Registrering (Faktiske)
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age strictly below 18 years of age at initial diagnosis
- Affiliate child or beneficiary of a social security scheme
- Child residing in metropolitan France
- Diagnosis of autoimmune haemolytic anemias, Evans syndrome and / or chronic Immune thrombocytopenic purpura
- Free, informed, written and signed consent
Exclusion Criteria:
- Diagnosis of constitutional haemolytic anemia
- Diagnosis of platelet constitutional disease
Studieplan
Hvordan er studiet utformet?
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
children with autoimmune haemolytic anemia
A blood sample of 2 times 2 to 5 ml additional maximum
|
A blood sample of 2 times 2 to 5 ml additional maximum
|
Children with Evans syndrome
A blood sample of 2 times 2 to 5 ml additional maximum
|
A blood sample of 2 times 2 to 5 ml additional maximum
|
Children with Immune thrombocytopenic purpura
A blood sample of 2 times 2 to 5 ml additional maximum
|
A blood sample of 2 times 2 to 5 ml additional maximum
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Complete sustainable remission (yes/no) for children with autoimmune haemolytic anemias
Tidsramme: At the screening
|
Absence of clinical signs of anemia (grade 0) And Hemoglobin > 11 g / dl And reticulocytes <120,000 / mm3 And haptoglobin> 10 mg / dl And bilirubin <10 mg / l or 17 μmol / l And no specific treatment for at least 12 months
|
At the screening
|
complete remission (yes/no) for children with autoimmune haemolytic anemias
Tidsramme: At the screening
|
Absence of clinical signs of anemia (grade 0) And Hemoglobin> 11 g / dl And reticulocytes <120,000 / mm3 Regardless of the level of haptoglobin or bilirubin And specific treatment in progress or interrupted for less than 12 months
|
At the screening
|
partial remission (yes/no) for children with autoimmune haemolytic anemias
Tidsramme: At the screening
|
Clinical Signs of Anemia (Grade 1 or 2) Or Hemoglobin from 7 to 11 g / dl Or reticulocytes> 120,000 / mm3 Regardless of the level of haptoglobin or bilirubin
|
At the screening
|
no response (yes/no) for children with autoimmune haemolytic anemias
Tidsramme: At the screening
|
Clinical Signs of Severe Anemia (Grade 3 or More) Or Hemoglobin <7 g / dl
|
At the screening
|
deceased patient (yes/no) for children with autoimmune haemolytic anemias
Tidsramme: At the screening
|
Death yes/no
|
At the screening
|
Complete sustainable remission (yes/no) for children with chronic immunologic thrombocytopenic purpura
Tidsramme: At the screening
|
Absence of clinical signs of haemorrhage (grade 0) And platelets> 100,000 / mm3 And no specific treatment for at least 12 months
|
At the screening
|
complete remission (yes/no) for children with chronic immunologic thrombocytopenic purpura
Tidsramme: At the screening
|
Absence of clinical signs of haemorrhage (grade 0) And platelets> 100,000 / mm3 And specific treatment in progress or interrupted for less than 12 months
|
At the screening
|
partial remission (yes/no) for children with chronic immunologic thrombocytopenic purpura
Tidsramme: At the screening
|
Clinical Signs of Hemorrhage (Grade 1 or 2) Or platelets between 30,000 and 100,000 / mm3
|
At the screening
|
no response (yes/no) for children with chronic immunologic thrombocytopenic purpura
Tidsramme: At the screening
|
Clinical Signs of Severe Hemorrhage (Grade 3 or Greater) Or Platelets <30,000 / mm3
|
At the screening
|
deceased patient (yes/no) for children with chronic immunologic thrombocytopenic purpura
Tidsramme: At the screening
|
Death yes/no
|
At the screening
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Yves PEREL, Pr, Bordeaux University Hsopital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Sykdommer i immunsystemet
- Autoimmune sykdommer
- Hematologiske sykdommer
- Blødning
- Hemoragiske lidelser
- Anemi
- Blodkoagulasjonsforstyrrelser
- Hudmanifestasjoner
- Trombocytopeni
- Blodplateforstyrrelser
- Trombotiske mikroangiopatier
- Purpura
- Purpura, trombocytopenisk
- Purpura, trombocytopenisk, idiopatisk
- Anemi, hemolytisk
- Anemi, hemolytisk, autoimmun
Andre studie-ID-numre
- CHUBX 2005/18
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Cytopeni
-
Children's Hospital Medical Center, CincinnatiFullførtAllogen stamcelletransplantasjon | Refraktær autoimmun cytopeni(er)Forente stater
-
Memorial Sloan Kettering Cancer CenterRekrutteringKlonal cytopeni av ubestemt betydning | CCUS klonal cytopeni av ubestemt betydningForente stater
-
Washington University School of MedicineBristol-Myers Squibb; Damon Runyon Cancer Research FoundationHar ikke rekruttert ennåKlonal cytopeni av ubestemt betydning | CCUS klonal cytopeni av ubestemt betydningForente stater
-
Uma BorateRekrutteringKlonal cytopeni av ubestemt betydningForente stater
-
Washington University School of MedicineGateway for Cancer Research; Servier Hellas Pharmaceuticals Ltd.RekrutteringKlonal cytopeni av ubestemt betydningForente stater
-
National Heart, Lung, and Blood Institute (NHLBI)RekrutteringKlonal cytopeni av ubestemt betydning | Klonal hematopoiesis av ubestemt potensialForente stater
-
National Institute of Allergy and Infectious Diseases...TilbaketrukketCTLA4 Haploinsuffisiens | Kronisk cytopeniForente stater
-
National Institutes of Health Clinical Center (CC)FullførtTrombocytopeni | BlodplatetransfusjonsrefraktærForente stater
-
National Institutes of Health Clinical Center (CC)Rekruttering
-
M.D. Anderson Cancer CenterSobi, Inc.Har ikke rekruttert ennåCytopeniForente stater
Kliniske studier på Blood sample
-
Hillel Yaffe Medical CenterUkjent
-
ExThera Medical Europe BVExThera Medical Corporation; Vivantes Clinic NeuköllnRekrutteringBlodstrømsinfeksjonFrankrike, Tyskland, Nederland, Østerrike, Belgia, Italia, Polen, Spania, Storbritannia
-
Ascensia Diabetes CareFullført
-
InSightecFocused Ultrasound FoundationRekruttering
-
Stanford UniversityRekrutteringVaskulære sykdommer | Slag | Hypertensjon | TIAForente stater
-
InSightecRekrutteringAlzheimers sykdomForente stater
-
Sykehuset i Vestfold HFOslo University Hospital; Dentsply Sirona ImplantsUkjentArtrose, hofte | Aorta sykdommerNorge
-
Bispebjerg HospitalUniversity College Absalon; Danske FysioterapeuterAktiv, ikke rekrutterendeJumpers kne | Patellar tendinopatiDanmark
-
MinYoung Kim, M.D.FullførtGlobal utviklingsforsinkelseKorea, Republikken